Literature DB >> 35930202

Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand.

Natthapat Thongsak1, Natthaporn Manojai2, Rathawit Apiputhipan2, Nicha Rongram3, Natnita Mattawanon4, Walaithip Bunyatisai1,5, Bandhita Plubin1,5, Nawapon Nakharutai1,5, Salinee Thumronglaohapun1,5, Pimwarat Srikummoon1,5, Kanokkan Wongsawat1, Patrinee Traisathit1,5,6, Nontiya Homkham7.   

Abstract

Although HIV pre-exposure prophylaxis (PrEP) is free in Thailand, many transgender women discontinue taking it after initiation. We determined the loss to follow-up (LTFU) rate of transgender women who initiated PrEP at the Mplus Foundation, Chiang Mai, Thailand, and identified associated risk factors using Cox proportional hazard models. Of 235 participants who initiated PrEP, 59 (55%) out of 108 remaining participants had reactive syphilis. The LTFU rate at 6 months was 38% (95% confidence interval [CI]: 29-48%). Multivariable analysis indicates that LTFU is independently associated with age ≥ 26 years old (adjusted hazard ratio [aHR] = 2.09; 95% CI: 1.06-4.14) and reactive syphilis (aHR = 1.98; 95% CI:1.01-3.88). Delayed appointment scheduling by the PrEP providers and the syphilis clinic was associated with transgender women having reactive syphilis, and the lockdown policy during the COVID-19 pandemic might have influenced them to discontinue PrEP and their subsequent LTFU.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Loss to follow-up; PrEP; Preventing HIV; Thailand; Transgender women

Year:  2022        PMID: 35930202      PMCID: PMC9362098          DOI: 10.1007/s10461-022-03782-7

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  39 in total

1.  Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Authors:  Robert M Grant; Sharon Mannheimer; James P Hughes; Yael Hirsch-Moverman; Avelino Loquere; Anupong Chitwarakorn; Marcel E Curlin; Maoji Li; K Rivet Amico; Craig W Hendrix; Peter L Anderson; Bonnie J Dye; Mark A Marzinke; Estelle Piwowar-Manning; Laura McKinstry; Vanessa Elharrar; Michael Stirratt; James F Rooney; Susan H Eshleman; Janet M McNicholl; Frits van Griensven; Timothy H Holtz
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

2.  Delivery of TDF/FTC for Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition in Young Adult Men Who Have Sex With Men and Transgender Women of Color Using a Urine Adherence Assay.

Authors:  Linden Lalley-Chareczko; Devon Clark; Caitlin Conyngham; Athena Zuppa; Ganesh Moorthy; Karam Mounzer; Helen Koenig
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

3.  Importance of Risk Perception: Predictors of PrEP Acceptance Among Thai MSM and TG Women at a Community-Based Health Service.

Authors:  Rosalyn Plotzker; Pich Seekaew; Jureeporn Jantarapakde; Supabhorn Pengnonyang; Deondara Trachunthong; Danai Linjongrat; Surang Janyam; Thitiyanun Nakpor; Sutinee Charoenying; Stephen Mills; Ravipa Vannakit; Michael Cassell; Praphan Phanuphak; Cheewanan Lertpiriyasuwat; Nittaya Phanuphak
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

4.  Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.

Authors:  Jared M Baeten; Renee Heffron; Lara Kidoguchi; Nelly R Mugo; Elly Katabira; Elizabeth A Bukusi; Stephen Asiimwe; Jessica E Haberer; Jennifer Morton; Kenneth Ngure; Nulu Bulya; Josephine Odoyo; Edna Tindimwebwa; Craig Hendrix; Mark A Marzinke; Norma C Ware; Monique A Wyatt; Susan Morrison; Harald Haugen; Andrew Mujugira; Deborah Donnell; Connie Celum
Journal:  PLoS Med       Date:  2016-08-23       Impact factor: 11.069

5.  Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.

Authors:  Akarin Hiransuthikul; Rena Janamnuaysook; Kanittha Himmad; Stephen J Kerr; Narukjaporn Thammajaruk; Tippawan Pankam; Kannapat Phanjaroen; Stephen Mills; Ravipa Vannakit; Praphan Phanuphak; Nittaya Phanuphak
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

6.  Barriers to using HIV pre-exposure prophylaxis (PrEP) and sexual behaviour after stopping PrEP: a cross-sectional study in Germany.

Authors:  Uwe Koppe; Ulrich Marcus; Stefan Albrecht; Klaus Jansen; Heiko Jessen; Barbara Gunsenheimer-Bartmeyer; Viviane Bremer
Journal:  BMC Public Health       Date:  2021-01-19       Impact factor: 3.295

7.  Pre-exposure prophylaxis (PrEP) uptake and service delivery adaptations during the first wave of the COVID-19 pandemic in 21 PEPFAR-funded countries.

Authors:  Michael Kerzner; Anindya K De; Randy Yee; Ryan Keating; Gaston Djomand; Sharon Stash; Sangeeta Rana; Allison Kimmel; Robyn Eakle; Sara Klucking; Pragna Patel
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

8.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

9.  Risk factors for loss to follow-up among at-risk HIV negative men who have sex with men participating in a research cohort with access to pre-exposure prophylaxis in coastal Kenya.

Authors:  Elizabeth W Wahome; Susan M Graham; Alexander N Thiong'o; Khamisi Mohamed; Tony Oduor; Evans Gichuru; John Mwambi; Elise M van der Elst; Eduard J Sanders
Journal:  J Int AIDS Soc       Date:  2020-10       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.